New Generation of Anthrax Prophylaxis and Therapy

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$432,829.00
Award Year:
2005
Program:
SBIR
Phase:
Phase I
Contract:
1R43AI066437-01
Award Id:
75958
Agency Tracking Number:
AI066437
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
Afg Biosolutions, Inc., 20358 Seneca Meadows Pky, Germantown, MD, 20876
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
KEN ALIBEK
() -
kalibek@gmu.edu
Business Contact:
SVELTLANA HOPKINS
(240) 361-1710
svetlana.hopkins@afgbio.com
Research Institute:
n/a
Abstract
DESCRIPTION (provided by applicant): This Phase I SBIR application addresses the NIAID call for high priority biodefense products such as novel vaccines and therapeutics to protect our nation against various biothreat agents. Although these types of proposals do not require a significant amount of preliminary data, we have already performed substantial preliminary experimental work that encourages us to pursue an innovative and revolutionary approach for developing anti-anthrax preventive and therapeutic preparations. Within a short 12-month study, we plan to prove its effectiveness by developing novel multivalent anti-anthrax antibodies and multivalent anthrax peptide vaccine. These preparations will be based on the use of antigens identified in the active centers of extracellular and membrane-bound metalloproteinases of Bacillus anthracis. We decided to use these targets for the following reasons: a) Bacterial proteinases are recognized as virulence factors in a number of infectious diseases b) Recent discoveries have made it possible to identify sequence motifs of metalloproteinases. Consequently, it is now possible to identify specific amino acid sequences of "virulent" metalloproteinases for use as peptide vaccine candidates and as peptide molecules for immunization to generate both polyclonal and monoclonal antibodies for the prophylaxis and treatment of anthrax c) It has been proven that short peptides are immunogenic, can be easily manufactured, may be used for production of highly pure vaccines and can be combined as "cocktails" of peptides for the development and manufacture of multivalent/multiepitope and multiagent vaccines and antibodies. We have already finished our "proof-of principle" study and propose to develop a new anthrax vaccine and anti-anthrax antibodies with the following specific aims: 1). Synthesis, purification and conjugation of peptide antigens as candidates for multivalent vaccine and antibody development; 2). Immunization of mice with the peptide vaccine candidates and testing of specific anti-anthrax immunity generated by a single peptide candidate and a combination thereof; 3). Generation of specific anti-anthrax antibodies against the selected peptides and testing their protective efficacy in the murine model.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government